- Acorda Therapeutics Inc ACOR shares dipped 27 percent to $18.77 after the company reported that it has received a Refusal to File letter from the FDA for INBRIJA regarding its previously filed NDA.
- Finish Line Inc FINL shares tumbled 19.6 percent to $8.38 after the company issued weak forecast for the second quarter and lowered its guidance for the year. The company also disclosed that its board has adopted a shareholder rights plan. FBR Capital downgraded Finish Line from Buy to Neutral, while Buckingham Research downgraded the stock from Neutral to Underperform.
- J.Jill Inc JILL shares dropped 15.5 percent to $9.91. J.Jill posted in-line Q2 earnings, but issued a weak outlook.
- CGG SA (ADR) CGG shares dropped 13.8 percent to $5.20 after tumbling 9.30 percent on Monday.
- Root9B Holdings Inc RTNB shares declined 11.5 percent to $2.31 after dipping 12.71 percent on Monday.
- Best Buy Co Inc BBY shares declined 10.5 percent to $55.90. Best Buy reported upbeat results for its second quarter and issued a strong forecast for the current quarter.
- Valeant Pharmaceuticals Intl Inc VRX fell 8 percent to $13.10. Mizuho lowered its price target on Valeant from $8 to $7.
- Fusion Telecommunications Int'l, Inc. FSNN shares dropped 7 percent to $2.13.
- Intellia Therapeutics Inc NTLA declined 7 percent to $19.38. Chardan Capital downgraded Intellia Therapeutics from Buy to Neutral.
- Helios and Matheson Analytics Inc HMNY shares dipped 6.4 percent to $3.06.
- Mesoblast limited (ADR) MESO shares dropped 6.2 percent to $6.09.
- Fang Holdings Ltd SFUN shares fell 6.1 percent to $3.40. SouFun Holdings reported a Q2 loss of $2.1 million on revenue of $110.1 million.
- Helen of Troy Limited HELE declined 6 percent to $91.05. Bank of America initiated coverage on Helen of Troy with an Underperform rating.
- Christopher & Banks Corporation CBK shares fell 4.1 percent to $1.40. Christopher & Banks posted a Q2 loss of $0.20 per share on revenue of $86.6 million.
- AveXis Inc AVXS dropped 4.1 percent to $93.07. Nomura initiated coverage on AveXis with a Reduce rating.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
